Core Insights - Brain-computer interface (BCI) technology is emerging as a transformative force, bridging theoretical exploration and practical application across various industries [1][5] - The "North Brain No. 1" project represents a significant breakthrough in China's BCI field, having successfully completed three human implantations with a 128-channel micro-system [5][6] - The BCI industry is still in its early stages, facing major challenges in core components, signal acquisition, and wireless transmission [5][7] Industry Developments - The BCI Industry Alliance announced the top ten innovative achievements in BCI for 2025, highlighting "North Brain No. 1" and several other advanced systems [6] - The forum emphasized the need for enhanced collaboration among government departments to guide the BCI industry's innovation and development [8] - Recommendations were made to strengthen technological research, optimize the industry ecosystem, and establish a robust patent and standards system for BCI technology [8][9] Clinical Progress - The clinical trials of "North Brain No. 1" have shown a language decoding accuracy exceeding 60% at the Xuanwu Hospital, indicating promising results [5] - Data collection and model calibration are ongoing, with multiple decoding teams actively working on patient data analysis [5] Future Outlook - The ultimate goal of BCI technology is not only to connect the brain with machines but also to link humanity with the future [10]

Investment Rating - The report maintains an "Overweight" rating for the industry [6] Core Insights - The National Healthcare Security Administration has established separate pricing for brain-computer interface (BCI) medical services, paving the way for clinical application fees [1] - The BCI technology is a promising frontier technology that connects the brain with external devices, with applications in healthcare, wellness, education, and entertainment [2] - The market size for brain-computer interfaces in China is projected to reach 3.2 billion yuan in 2024, with a growth rate of 18.8%, and expected to grow to 5.58 billion yuan by 2027 [2] - National and local policies are accelerating the development of the BCI industry, with plans to cultivate influential tech companies and promote large-scale commercialization of BCI products by 2030 [3] Summary by Sections - **Investment Recommendations**: The report suggests focusing on companies such as Sanbo Brain Science, Aipeng Medical, and Innovation Medical, as the regulatory framework supports the clinical application of BCI technologies [4]

Core Viewpoint - The company, Beixin Source (300352), highlights the potential of brain-computer interface technology as a cutting-edge field in technology, emphasizing its capability for secure communication between humans and objects, as well as between objects themselves [1] Group 1: Technology and Application - Brain-computer interface technology is recognized as a frontier technology in the current tech landscape [1] - The technology of Xinyuan Mixin has potential applications in secure communication within the brain-computer interface domain, indicating a technological compatibility and application possibility [1] Group 2: Current Business Impact - Currently, there has been no substantial impact on the company's main business operations from the brain-computer interface technology, and its direct contribution remains unclear [1]

Core Viewpoint - Huawei Technologies Co., Ltd. has recently published a patent application for a "signal processing method and related device" applicable in the field of brain-computer interface (BCI) technology [1] Group 1: Patent Details - The patent involves acquiring a first signal, which is collected from brain tissue, and obtaining downstream feedback signals [1] - The method processes the first signal based on the feedback signal, rather than directly inputting the first signal into a decoding device, ensuring long-term stability in signal encoding and decoding [1] - This approach helps to avoid the degradation of signal encoding and decoding stability due to non-stationarity of the first signal [1]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月10日，中国植入式脑机接口领域的创新先锋—— 阶梯医疗宣布完成 3.5亿元 人民币B轮融资 ， 这是中国植入式脑机接口行业历史上最大的一笔融资 。 本轮融资由 启明创投 、 奥博资本 、 礼来亚洲基金 等知名投资机构共同领投，天使轮投资机构 源来资本 持续跟投， 启峰资本 担任财务顾问。 本轮资金将用于加速产品临床试验、新一代技术研发以及医疗级MEMS生产基地建设，为脑机接口技术的商 业化落地提供强力支撑。 # 公司介绍 市场表现 阶梯医疗成立于2021年8月，总部位于上海，专注于微创植入式脑机接口技术的研发与应用。公司成功研制出 中国首款符合医疗器械标准的高通量植入式脑机接口系统，是中国首个完成注册性型式检验的侵入式脑机接口 产品。凭借该项目，阶梯医疗入选工信部2023年未来产业创新任务"揭榜挂帅"项目名单，是上海市唯一获评的 植入式脑机接口企业，并获得上海市2024年度"科技创新行动计划"脑机接口项目支持。 产品与技术介绍 技术特点 阶 ...

国内首个完成注册性型式检验的植入式脑机接口企业。 成立于2021年8月 的 阶梯医疗专注于微创植入式脑机接口技术的研发与应用。与Neuralink一样， 阶梯医疗选择了技术难度与应用天花板最高的侵入式脑机接口技术路径，并成功研制出中国首款符合 医疗器械标准的高通量植入式脑机接口系统，旨在帮助瘫痪患者完成复杂的脑控任务，是中国首个完 成注册性型式检验的侵入式脑机接口产品。 目前，阶梯医疗已与国内多家顶尖医院合作，开展了累积超过50例脑机接口相关研究者发起的临床 研究（IIT），取得了显著的临床效果，并建成全球规模最大的柔性电极人体单细胞数据集。阶梯医 疗计划于2025年启动国内首个侵入式脑机接口长期埋植前瞻性临床试验（FIM），2026年进一步推 进大规模临床试验，为产品注册上市铺平道路。 在神经电极技术方面，阶梯医疗实现了革命性突破：采用超柔性电极设计，尺寸仅为头发丝的 1/100（Neuralink的1/5），柔软程度优于Neuralink数百倍，使得脑组织很难"感受到"电极的"外 来侵入"，首次开发出未形成免疫瘢痕的神经电极界面，保证了长期稳定的神经活动记录。通过引入 半导体微纳加工工艺，公司解决了医疗级 ...